Weather , , 0°C

Hot Flashes Market Trends and Growth Analysis, Clinical Developmental Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast (in the 7MM)

 Breaking News
  • No posts were found

Hot Flashes Market Trends and Growth Analysis, Clinical Developmental Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast (in the 7MM)

October 27
14:30 2021
Hot Flashes Market Trends and Growth Analysis, Clinical Developmental Activities, Leading Companies, Emerging Therapies, and Epidemiology Forecast (in the 7MM)
Delveinsight Business Research LLP
DelveInsight’s “Hot Flashes Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hot Flashes Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hot Flashes market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hot Flashes: An Overview

Vasomotor symptoms (VMS) or Hot Flashes are the most commonly reported menopausal symptoms, characterized by a sudden increase of blood flow, often to the face, neck, and chest, that causes the sensation of extreme heat and profuse sweating. When symptoms occur at night they are called “night sweats” and can cause significant sleep disturbances. Episodes of vasomotor symptoms can last 1 to 5 minutes and can be associated with perspiration, flushing, chills, anxiety, and even heart palpitations.

Hot Flashes Market Key Facts

  • The severity of hot flashes is described as mild, moderate, and severe. In 2018, prevalent cases of mild, moderate, and severe hot flashes in the US were 11,762,902, 4,485,612, and 2,678,118 respectively. In 2018, the prevalent population of hot flashes in Japan was estimated as 2,829,757, 1,079,087, and 644,265 for mild, moderate, and severe symptoms.

  • Among the European countries, Germany had the highest prevalent population of Vasomotor Symptoms, followed by France. On the other hand, Spain had the lowest prevalent population of Vasomotor Symptoms.

  • As per the estimates, the United States has the highest prevalent population of hot flashes associated with post-menopause with 18,926,632 cases in 2018. Japan had the lowest prevalent population with 4,553,108 prevalent cases of hot flashes in 2018.

Get FREE sample copy at: Hot Flashes Therapeutics Market

Key Benefits of Hot Flashes Market Report

  • The report provides an in-depth analysis of Hot Flashes Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Hot Flashes Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Hot Flashes current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Hot Flashes market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Hot Flashes Market

The market size of hot flashes associated with post-menopause in the seven major markets was found to be 1,755.8 Million in 2018, which is expected to increase during the forecast period.

Hot Flashes market size is expected to increase due to the increasing awareness, research, and development for the production of therapy, and the launch of the therapies in the coming years.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hot Flashes market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Hot Flashes market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Hot Flashes Epidemiology

The epidemiology section covers insights about the historical and current Hot Flashes patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Hot Flashes Epidemiology Segmentation

  • Total Prevalent Pool of Vasomotor Symptoms (Hot Flashes/Night Sweats)

  • Severity-specific Prevalent Pool of Hot Flashes

Hot Flashes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hot Flashes market or expected to get launched in the market during the study period. The analysis covers Hot Flashes market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Hot Flashes Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Many potential systemic therapies are being investigated for the management of hot flashes associated with post-menopause. It is expected that the market size of hot flashes associated with menopause will increase in the coming years owing to the launch of emerging therapies. 

Some of the key companies developing therapies for the Hot Flashes include:

  • Mithra Pharmaceuticals

  • Astellas Pharma

  • Bayer

  • Nerre Therapeutics

  • Fervent Pharmaceuticals

  • Sojournix

And others.

Hot Flashes Therapies covered in the report includes:

  • Donesta 

  • Fezolinetant 

  • NT-814

  • FP-101

  • SJX-653

And many more.

Request for Sample @ Hot Flashes Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Hot Flashes Competitive Intelligence Analysis

4. Hot Flashes Market Overview at a Glance

5. Hot Flashes Disease Background and Overview

6. Hot Flashes Patient Journey

7. Hot Flashes Epidemiology and Patient Population

8. Hot Flashes Treatment Algorithm, Current Treatment, and Medical Practices

9. Hot Flashes Unmet Needs

10. Key Endpoints of Hot Flashes Treatment

11. Hot Flashes Marketed Products

12. Hot Flashes Emerging Therapies

13. Hot Flashes Seven Major Market Analysis

14. Attribute Analysis

15. Hot Flashes Market Outlook (7 major markets)

16. Hot Flashes Access and Reimbursement Overview

17. KOL Views on the Hot Flashes Market.

18. Hot Flashes Market Drivers

19. Hot Flashes Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/hot-flashes-market

Healthcare Blogs

von Willebrand disease (VWD Market Trends and Growth Analysis

Globally, a considerable fraction of the population suffers from Von Willebrand Disease (VWD). As per DelveInsight estimates, the total diagnosed prevalence of von Willebrand disease was 12,505 in the US in 2020, which is further expected to increase with a CAGR of 1.23% by 2030. The underdiagnosed, misdiagnosed, and high cost of treatment poses a significant challenge which often leads to patients’ quality of life and life expectancy. To meet the unmet needs at the treatment front, several leading companies including CSL Behring Octapharma, Grifols, Takeda, Sanofi, and others, are proactively working in the therapeutics landscape. For more details, visit: von Willebrand disease (VWD) Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

December 2021
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Categories